Negative
●
Proactive Investors
●
2 months ago
HSBC has downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', arguing that a recent trial failure has removed the central pillar of its bull case and left a tougher path ahead. The bank cut its target price to 13,750p from 16,500p, implying limited upside.